{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:53:48Z","timestamp":1790621628832,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2017,7,23]],"date-time":"2017-07-23T00:00:00Z","timestamp":1500768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1038\/gt.2017.52","type":"journal-article","created":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T10:40:19Z","timestamp":1498214419000},"page":"529-533","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":171,"title":["The clinical landscape for SMA in a new therapeutic era"],"prefix":"10.1038","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5490-1697","authenticated-orcid":false,"given":"K","family":"Talbot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E F","family":"Tizzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,23]]},"reference":[{"key":"BFgt201752_CR1","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/S1474-4422(13)70221-7","volume":"12","author":"ME Cudkowicz","year":"2013","unstructured":"Cudkowicz ME, van den Berg LH, Shefner JM, Mitsumoto H, Mora JS, Ludolph A et al. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurol 2013; 12: 1059\u20131067.","journal-title":"Lancet Neurol"},{"key":"BFgt201752_CR2","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.bbagrm.2016.12.008","volume":"1860","author":"RN Singh","year":"2017","unstructured":"Singh RN, Howell MD, Ottesen EW, Singh NN . Diverse role of survival motor neuron protein. Biochim Biophys Acta 2017; 1860: 299\u2013315.","journal-title":"Biochim Biophys Acta"},{"key":"BFgt201752_CR3","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nrn2670","volume":"10","author":"AH Burghes","year":"2009","unstructured":"Burghes AH, Beattie CE . Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick? Nat Rev Neurosci 2009; 10: 597\u2013609.","journal-title":"Nat Rev Neurosci"},{"key":"BFgt201752_CR4","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S Lefebvre","year":"1995","unstructured":"Lefebvre S, Burglen L, Reboullet S, Clermont O, Burlet P, Viollet L et al. Identification and characterization of a spinal muscular atrophy- determining gene [see comments]. Cell 1995; 80: 155\u2013165.","journal-title":"Cell"},{"key":"BFgt201752_CR5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s00439-008-0598-1","volume":"125","author":"L Alias","year":"2009","unstructured":"Alias L, Bernal S, Fuentes-Prior P, Barcelo MJ, Also E, Martinez-Hernandez R et al. Mutation update of spinal muscular atrophy in Spain: molecular characterization of 745 unrelated patients and identification of four novel mutations in the SMN1 gene. Hum Genet 2009; 125: 29\u201339.","journal-title":"Hum Genet"},{"key":"BFgt201752_CR6","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/(SICI)1098-1004(200003)15:3<228::AID-HUMU3>3.0.CO;2-9","volume":"15","author":"B Wirth","year":"2000","unstructured":"Wirth B . An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA). Hum Mutat 2000; 15: 228\u2013237.","journal-title":"Hum Mutat"},{"key":"BFgt201752_CR7","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1086\/338627","volume":"70","author":"M Feldkotter","year":"2002","unstructured":"Feldkotter M, Schwarzer V, Wirth R, Wienker TF, Wirth B . Quantitative analyses of smn1 and smn2 based on real-time lightcycler pcr: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet 2002; 70: 358\u2013368.","journal-title":"Am J Hum Genet"},{"key":"BFgt201752_CR8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.yexcr.2004.03.022","volume":"296","author":"AK Gubitz","year":"2004","unstructured":"Gubitz AK, Feng W, Dreyfuss G . The SMN complex. Exp Cell Res 2004; 296: 51\u201356.","journal-title":"Exp Cell Res"},{"key":"BFgt201752_CR9","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","volume":"388","author":"RS Finkel","year":"2016","unstructured":"Finkel RS, Chiriboga CA, Vajsar J, Day JW, Montes J, De Vivo DC et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet 2016; 388: 3017\u20133026.","journal-title":"Lancet"},{"key":"BFgt201752_CR10","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.nmd.2009.11.014","volume":"20","author":"AM Glanzman","year":"2010","unstructured":"Glanzman AM, Mazzone E, Main M, Pelliccioni M, Wood J, Swoboda KJ et al. The children's hospital of philadelphia infant test of neuromuscular disorders (CHOP INTEND): test development and reliability. Neuromuscul Disord 2010; 20: 155\u2013161.","journal-title":"Neuromuscul Disord"},{"key":"BFgt201752_CR11","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.4155\/fmc.15.101","volume":"7","author":"NN Singh","year":"2015","unstructured":"Singh NN, Lee BM, DiDonato CJ, Singh RN . Mechanistic principles of antisense targets for the treatment of spinal muscular atrophy. Future Med Chem 2015; 7: 1793\u20131808.","journal-title":"Future Med Chem"},{"key":"BFgt201752_CR12","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1177\/0883073807305788","volume":"22","author":"CH Wang","year":"2007","unstructured":"Wang CH, Finkel RS, Bertini ES, Schroth M, Simonds A, Wong B et al. Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol 2007; 22: 1027\u20131049.","journal-title":"J Child Neurol"},{"key":"BFgt201752_CR13","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1053\/j.semperi.2015.03.006","volume":"39","author":"HC Phan","year":"2015","unstructured":"Phan HC, Taylor JL, Hannon H, Howell R . Newborn screening for spinal muscular atrophy: Anticipating an imminent need. Semin Perinatol 2015; 39: 217\u2013229.","journal-title":"Semin Perinatol"},{"key":"BFgt201752_CR14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00415-005-0912-y","volume":"253","author":"I Cusco","year":"2006","unstructured":"Cusco I, Barcelo MJ, Rojas-Garcia R, Illa I, Gamez J, Cervera C et al. SMN2 copy number predicts acute or chronic spinal muscular atrophy but does not account for intrafamilial variability in siblings. J Neurol 2006; 253: 21\u201325.","journal-title":"J Neurol"},{"key":"BFgt201752_CR15","first-page":"xxxii","volume-title":"Spinal Muscular Atrophy: Disease Mechanisms and Therapy","author":"M Perez Garcia","year":"2017","unstructured":"Perez Garcia M, Kong L, Sumner C, Tizzano E Developmental Aspects and Pathological findigins in Spinal Muscular Atrophy. In: Sumner CJ, Paushkin S, Ko C-P editors. Spinal Muscular Atrophy: Disease Mechanisms and Therapy. Elsevier\/Academic Press: Amsterdam, The Netherlands, 2017, p xxxii 474 pages."},{"key":"BFgt201752_CR16","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1212\/WNL.0b013e318271f7e4","volume":"79","author":"P Kaufmann","year":"2012","unstructured":"Kaufmann P, McDermott MP, Darras BT, Finkel RS, Sproule DM, Kang PB et al. Prospective cohort study of spinal muscular atrophy types 2 and 3. Neurology 2012; 79: 1889\u20131897.","journal-title":"Neurology"},{"key":"BFgt201752_CR17","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.nmd.2015.10.006","volume":"26","author":"E Mercuri","year":"2016","unstructured":"Mercuri E, Finkel R, Montes J, Mazzone ES, Sormani MP, Main M et al. Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials. Neuromuscul Disord 2016; 26: 126\u2013131.","journal-title":"Neuromuscul Disord"},{"key":"BFgt201752_CR18","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","volume":"86","author":"CA Chiriboga","year":"2016","unstructured":"Chiriboga CA, Swoboda KJ, Darras BT, Iannaccone ST, Montes J, De Vivo DC et al. Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy. Neurology 2016; 86: 890\u2013897.","journal-title":"Neurology"},{"key":"BFgt201752_CR19","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.molmed.2012.11.002","volume":"19","author":"G Hamilton","year":"2013","unstructured":"Hamilton G, Gillingwater TH . Spinal muscular atrophy: going beyond the motor neuron. Trends Mol Med 2013; 19: 40\u201350.","journal-title":"Trends Mol Med"},{"key":"BFgt201752_CR20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/NEN.0000000000000144","volume":"74","author":"BN Harding","year":"2015","unstructured":"Harding BN, Kariya S, Monani UR, Chung WK, Benton M, Yum SW et al. Spectrum of neuropathophysiology in spinal muscular atrophy type I. J Neuropathol Exp Neurol 2015; 74: 15\u201324.","journal-title":"J Neuropathol Exp Neurol"},{"key":"BFgt201752_CR21","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1101\/gad.256644.114","volume":"29","author":"Y Hua","year":"2015","unstructured":"Hua Y, Liu YH, Sahashi K, Rigo F, Bennett CF, Krainer AR . Motor neuron cell-nonautonomous rescue of spinal muscular atrophy phenotypes in mild and severe transgenic mouse models. Genes Dev 2015; 29: 288\u2013297.","journal-title":"Genes Dev"},{"key":"BFgt201752_CR22","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nature10485","volume":"478","author":"Y Hua","year":"2011","unstructured":"Hua Y, Sahashi K, Rigo F, Hung G, Horev G, Bennett CF et al. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature 2011; 478: 123\u2013126.","journal-title":"Nature"},{"key":"BFgt201752_CR23","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1177\/0883073815627882","volume":"31","author":"M Hache","year":"2016","unstructured":"Hache M, Swoboda KJ, Sethna N, Farrow-Gillespie A, Khandji A, Xia S et al. Intrathecal injections in children with spinal muscular atrophy: nusinersen clinical trial experience. J Child Neurol 2016; 31: 899\u2013906.","journal-title":"J Child Neurol"},{"key":"BFgt201752_CR24","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S1474-4422(17)30085-6","volume":"16","author":"E Bertini","year":"2017","unstructured":"Bertini E, Dessaud E, Mercuri E, Muntoni F, Kirschner J, Reid C et al. Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 2017; 16: 513\u2013522.","journal-title":"Lancet Neurol"},{"key":"BFgt201752_CR25","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.ajhg.2017.01.005","volume":"100","author":"M Riessland","year":"2017","unstructured":"Riessland M, Kaczmarek A, Schneider S, Swoboda KJ, Lohr H, Bradler C et al. Neurocalcin delta suppression protects against spinal muscular atrophy in humans and across species by restoring impaired endocytosis. Am J Hum Genet 2017; 100: 297\u2013315.","journal-title":"Am J Hum Genet"},{"key":"BFgt201752_CR26","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.neurobiolaging.2013.09.030","volume":"35","author":"BJ Turner","year":"2014","unstructured":"Turner BJ, Alfazema N, Sheean RK, Sleigh JN, Davies KE, Horne MK et al. Overexpression of survival motor neuron improves neuromuscular function and motor neuron survival in mutant SOD1 mice. Neurobiol Aging 2014; 35: 906\u2013915.","journal-title":"Neurobiol Aging"},{"key":"BFgt201752_CR27","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1080\/14712598.2017.1271872","volume":"17","author":"EH Niks","year":"2017","unstructured":"Niks EH, Aartsma-Rus A . Exon skipping: a first in class strategy for Duchenne muscular dystrophy. Expert Opin Biol Ther 2017; 17: 225\u2013236.","journal-title":"Expert Opin Biol Ther"},{"key":"BFgt201752_CR28","doi-asserted-by":"publisher","first-page":"14454","DOI":"10.1038\/ncomms14454","volume":"8","author":"NE Bengtsson","year":"2017","unstructured":"Bengtsson NE, Hall JK, Odom GL, Phelps MP, Andrus CR, Hawkins RD et al. Muscle-specific CRISPR\/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy. Nat Commun 2017; 8: 14454.","journal-title":"Nat Commun"},{"key":"BFgt201752_CR29","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.nmd.2005.07.005","volume":"15","author":"E Bertini","year":"2005","unstructured":"Bertini E, Burghes A, Bushby K, Estournet-Mathiaud B, Finkel RS, Hughes RA et al. 134th ENMC International Workshop: Outcome Measures and Treatment of Spinal Muscular Atrophy, 11-13 February 2005, Naarden, The Netherlands. Neuromuscul Disord 2005; 15: 802\u2013816.","journal-title":"Neuromuscul Disord"},{"key":"BFgt201752_CR30","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1055\/s-2007-973741","volume":"27","author":"S Rudnik-Schoneborn","year":"1996","unstructured":"Rudnik-Schoneborn S, Forkert R, Hahnen E, Wirth B, Zerres K . Clinical spectrum and diagnostic criteria of infantile spinal muscular atrophy: further delineation on the basis of SMN gene deletion findings. Neuropediatrics 1996; 27: 8\u201315.","journal-title":"Neuropediatrics"},{"key":"BFgt201752_CR31","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1159\/000052118","volume":"45","author":"S Rudnik-Schoneborn","year":"1996","unstructured":"Rudnik-Schoneborn S, Hausmanowa-Petrusewicz I, Borkowska J, Zerres K . The predictive value of achieved motor milestones assessed in 441 patients with infantile spinal muscular atrophy types II and III. Eur Neurol 1996; 45: 174\u2013181.","journal-title":"Eur Neurol"},{"key":"BFgt201752_CR32","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","volume":"83","author":"RS Finkel","year":"2014","unstructured":"Finkel RS, McDermott MP, Kaufmann P, Darras BT, Chung WK, Sproule DM et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology 2014; 83: 810\u2013817.","journal-title":"Neurology"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/gt201752.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/gt201752","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/gt.2017.52","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/gt201752.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:34:28Z","timestamp":1684416868000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/gt201752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,23]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["BFgt201752"],"URL":"https:\/\/doi.org\/10.1038\/gt.2017.52","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,23]]},"assertion":[{"value":"3 March 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}